9 active not recruiting. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Active not recruiting 9 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification - Lupus Nephritis (LN), Chronic Kidney Disease | Phase 1 / Phase 2 | Active not recruiting | Hospital Civil Juan I. Menchaca | 30 | 2026-05-28 | 2026-07-01 |
| A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment RG002C0106 - Renal Impairments, IgA Nephropathy (IgAN) | Phase 1 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 24 | 2026-03-15 | 2026-10-15 |
| A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease SYNCAR-001, STK-009 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Active not recruiting | Synthekine | 48 | 2025-04-29 | 2026-07-10 |
| A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases CNTY-101, IL-2, Lymphodepleting Chemotherapy - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Active not recruiting | Century Therapeutics, Inc. | 6 | 2025-02-06 | 2026-01-08 |
| CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 KYV-101, Cyclophosphamide, Fludarabine - Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis | Phase 1 | Active not recruiting | David Porter | 24 | 2024-08-05 | 2026-09-21 |
| Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) SC291 - Lupus Erythematosus, Systemic Lupus Erythematosus | Phase 1 | Active not recruiting | Sana Biotechnology | 7 | 2024-04-29 | 2025-11-25 |
| AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus AB-101, Cyclophosphamide, Fludarabine - Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | Phase 1 | Active not recruiting | Artiva Biotherapeutics, Inc. | 51 | 2024-04-03 | 2025-12-10 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis Recombinant Humanized Monoclonal Antibody MIL62 Injection, placebo - Lupus Nephritis | Phase 1 / Phase 2 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 41 | 2021-11-26 | 2025-07-02 |
Lupus Nephritis (8) · Lupus Erythematosus, Systemic (5) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Autoimmune Diseases (2) · Glomerulonephritis, IGA (2) · Granulomatosis with Polyangiitis (2) · Microscopic Polyangiitis (2) · Myositis (2) · Scleroderma, Diffuse (2) · Scleroderma, Systemic (2) · Churg-Strauss Syndrome (1) · Dermatomyositis (1) · Glomerulonephritis, Membranous (1) · Polymyositis (1) · Renal Insufficiency, Chronic (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Immune System Diseases (9) · Kidney Diseases (9) · Male Urogenital Diseases (9) · Nephritis (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Connective Tissue Diseases (8) · Skin and Connective Tissue Diseases (8) · Autoimmune Diseases (7) · Skin Diseases (5) · Nervous System Diseases (4) · Cardiovascular Diseases (3)
Cyclophosphamide (3) · fludarabine (3) · Interleukin-2 (1) · Rituximab (1) · Tablets (1) · dapagliflozin (1) · obinutuzumab (1)
Alpine Immune Sciences, Inc. (1) · Artiva Biotherapeutics, Inc. (1) · Beijing Mabworks Biotech Co., Ltd. (1) · Century Therapeutics, Inc. (1) · David Porter (1) · Hospital Civil Juan I. Menchaca (1) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. (1) · Sana Biotechnology (1) · Synthekine (1)
United States (6) · China (2) · Australia (1) · Mexico (1) · Puerto Rico (1) · South Korea (1)